Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
Giuseppe Lombardi , Luisa Bellu , Veronica Villani , Simona Rizzato , Marco Russo , Mariantonia Carosi , Elisa De Carlo , Lorena Biasini , Marina Paola Gardiman , Pasquale Fiduccia , Ardi Pambuku , Alessandro Della Puppa , Miran Skrap , Franco Servadei , Domenico D'Avella , Carmine Maria Carapella , Mario Caccese , Roberta Bertorelle , Andrea Pace , Vittorina Zagonel
A LARGE, MULTICENTER, RETROSPECTIVE STUDY TO IDENTIFY A CUT-OFF OF MGMT METHYLATION STATUS BY QUANTITATIVE PYROSEQUENCING APPROACH IN PATIENTS (PTS) WITH GLIOBLASTOMA (GBM). Background: MGMT promoter methylation status representsan important prognostic factor for GBM PTS in terms of progression free survival (PFS) and overall survival (OS). Quantitative pyrosequencing approach is a valid alternative to methylation-specific PCR but a cut-off value in still unclear. We performed a large, multicenter, retrospective study to identify a real cut-off value to discriminate its impact on clinical outcome in terms of PFS and OS. Methods: Retrospectively, from italian neuro-oncology centers, we collected GBM PTS from 2005 to 2016 with assessment of MGMT promoter methylation by pyrosequencing approach evaluating CpG islands from 74 to 83. Other inclusion criteria were: confirmed histological diagnoses of GBM, ECOG PS ≥2, treatment with concomitant radiation therapy and temozolomide. Kaplan-Maier method was used to estimate the survival curves and ROC curve for defining cut-off value for PFS and OS. Results: 376 GBM PTS were enrolled;median age was 62 ys (25-86); ECOG PS was 0 in 129 PTS, 1 in 160 PTS, 2 in 87 PTS; 212 PTS (58%) had a complete resection. 67 PTS (18%) received a second surgery. Median PFS and OS was 8.6 and 14.3 months. The optimal cut-off value to identify a strong prognostic value of MGMT methylation status in terms of PFS and OS, was 26% (sensitivity 72%, specificity 61%, accuracy 71%) and 24% of methylation (sensitivity 72%, specificity 61%, accuracy 71%), respectively. On multivariate analyses, corrected for age, KPS, type of surgery and second surgery, the MGMT cut-off values remained significantly correlated to longer PFS (HR = 0.5, 95%CI 0.4-0.7) and OS (HR = 0.47, 95% CI 0.3-0.6). Conclusions: From this large, multicenter study, we identify, by pyrosequencing approach, a strong prognostic value of MGMT methylation, in terms of PFS and OS. This value could be used as stratification factor in prospective clinical trials.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Paul James Mulholland
2022 ASCO Annual Meeting
First Author: Shiao-Pei S. Weathers
2021 ASCO Annual Meeting
First Author: Ryan C Miller
2023 ASCO Annual Meeting
First Author: Dinu Stefan